Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure-Reference-Cited by-同舟云学术

Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure

Published:2014-03-27 Issue:4 Volume:39 Page:432-438
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Shihmanter R.¹,Nulman I.²,Goland S.³,Caspi A.³,Bar-Haim A.⁴,Harary I.⁴,Berkovitch M.⁵,Arcavi L.¹

Affiliation:

1. Clinical Pharmacology Unit; Kaplan Medical Center; Hebrew University and Hadassah Medical School; Rehovot Jerusalem Israel

2. Division of Clinical Pharmacology and Toxicology; The Hospital for Sick Children; University of Toronto; Toronto ON Canada

3. Department of Cardiology; Kaplan Medical Center; Hebrew University and Hadassah Medical School; Rehovot Jerusalem Israel

4. Biochemistry and Pharmacogenetics Laboratory; Assaf Harofeh Medical Center; Zerifin Israel

5. Clinical Pharmacology Unit; Assaf Harofeh Medical Center; Zerifin Israel

Funder

Din Diagnostic Ltd.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12154/fullpdf

Reference38 articles.

1. The global epidemiology of heart failure;Young;Med Clin North Am,2004

2. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee;Heart Disease and Stroke Statistic Update;Circulation,2013

3. ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Jancy;Circulation,2013

4. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET);Poole-Wilson;Lancet,2003

5. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study;Packer;Circulation,2002

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases;Bulletin of Siberian Medicine;2023-01-20

2. Population Pharmacokinetic−Pharmacodynamic Modeling of Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction;Journal of Korean Medical Science;2023

3. Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report;Medicina;2021-09-10

4. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle;Pharmacogenomics;2018-09-01

5. Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure;Journal of Pharmacy Practice;2018-06-19